Research programme: glioblastoma therapy - Royer Biomedical

Drug Profile

Research programme: glioblastoma therapy - Royer Biomedical

Alternative Names: AppliGel - 5-FU; Fluorouracil implant - Royer Biomedical

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Royer Biomedical
  • Class Antineoplastics; Pyrimidinones; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Glioblastoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Glioblastoma in USA (Intracerebral, Implant)
  • 06 Jun 2012 Early research in Glioblastoma in USA (Intracranial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top